| Minnesota                                                               | 41-1448837                                   |
|-------------------------------------------------------------------------|----------------------------------------------|
| (State      or other jurisdictionof      incorporation or organization) | (I.R.S.      Employer Identification Number) |

| Large      accelerated filer       o            | Accelerated      filer                      o |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                                                |                                                                                            |
| Non-accelerated      filer          o | Smaller      reporting company       x                                      |

----

SPECTRASCIENCE, INC.

| PART      I   | FINANCIAL      INFORMATION:                                                                           |   |   | 3      |   |
|---------------|-------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|          |                                                                                                  |   |   |   |   |
| Item      1.  | Financial      Statements (Unaudited)                                                                 |   |   | 3      |   |
|          |                                                                                                  |   |   |   |   |
| Item      2.  | Management’s      Discussion and Analysis of Financial Condition and Results of      Operations |   |   | 11     |   |
|          |                                                                                                  |   |   |   |   |
| Item      3.  | Quantitative      and Qualitative Disclosures About Market Risk                                       |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      4.  | Controls      and Procedures                                                                          |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| PART      II  | OTHER      INFORMATION                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      1.  | Legal      Proceedings                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      1A. | Risk      Factors                                                                                     |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      2.  | Unregistered      Sales of Equity Securities and Use of Proceeds                                      |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      3.  | Defaults      Upon Senior Securities                                                                  |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      4.  | (Removed      and Reserved)                                                                           |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      5.  | Other      Information                                                                                |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| Item      6.  | Exhibits                                                                                              |   |   | 14     |   |
|          |                                                                                                  |   |   |   |   |
| SIGNATURES    |                                                                                                  |   | 15     |   |

----

|                                                                                                                                                             |   | June      30, 2010 |          |   | December 31,2009 |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|---------------|--------|------------------|--------|
|                                                                                                                                                             |   | (Unaudited)             |          |   | (Audited)        |   |
| ASSETS                                                                                                                                                           |   |                    |          |   |             |   |
| Current      assets:                                                                                                                                             |   |                    |          |   |             |   |
| Cash      and cash equivalents                                                                                                                                   |   | $                       | 4,775,313     |   |             | $      | 3,408,237 |   |
| Accounts      receivable (net)                                                                                                                                   |   |                    | 29,106        |   |             |   | 40,271 |   |
| Inventories      (net of allowances)                                                                                                                             |   |                    | 452,441       |   |             |   | 405,675 |   |
| Prepaid      expenses and other current assets                                                                                                                   |   |                    | 102,698       |   |             |   | 195,568 |   |
| Total      current assets                                                                                                                                        |   |                    | 5,359,558     |   |             |   | 4,049,751 |   |
| Fixed      assets, net                                                                                                                                           |   |                    | 898,587       |   |             |   | 1,139,839 |   |
| Patents,      net                                                                                                                                                |   |                    | 2,791,200     |   |             |   | 2,915,984 |   |
| TOTAL      ASSETS                                                                                                                                                |   | $                       | 9,049,345     |   |             | $      | 8,105,574 |   |
|                                                                                                                                                             |   |                    |          |   |             |   |   |   |
| LIABILITIES      AND SHAREHOLDERS’ EQUITY                                                                                                                  |   |                    |          |   |             |   |   |   |
| Current      liabilities:                                                                                                                                        |   |                    |          |   |             |   |   |   |
| Accounts      payable                                                                                                                                            |   | $                       | 231,149       |   |             | $      | 219,783 |   |
| Accrued      liabilities                                                                                                                                         |   |                    | 103,172       |   |             |   | 167,475 |   |
| Total      current liabilities                                                                                                                                   |   |                    | 334,321       |   |             |   | 387,258 |   |
|                                                                                                                                                             |   |                    |          |   |             |   |   |   |
| SHAREHOLDERS’      EQUITY                                                                                                                                  |   |                    |          |   |             |   |   |   |
|                                                                                                                                                             |   |                    |          |   |             |   |   |   |
| Series      B Convertible Preferred Stock, $.01 par value:                                                                                                       |   |                    |          |   |             |   |   |   |
| Authorized      – 25,000,000; shares issued and outstanding – 2,885,000 shares at June 30,      2010 (25,000,000 shares at December 31, 2009)        |   |                    | 28,850        |   |             |   | 250,000 |   |
| Series      C Convertible Preferred Stock, $0.01 par value:                                                                                                      |   |                    |          |   |             |   |   |   |
| Authorized—25,000,000      shares; shares issued and outstanding – 15,766,155 shares at June 30, 2010      (-0- shares at December 31, 2009)         |   |                    | 157,662  |   |             |   | -  |   |
| Common      stock, $.01 par value:                                                                                                                               |   |                    |          |   |             |   |   |   |
| Authorized—175,000,000      shares; shares issued and outstanding – 92,657,785 shares at June 30, 2010      (70,142,615 shares at December 31, 2009) |   |                    | 926,578       |   |             |   | 701,426 |   |
| Additional      paid-in capital                                                                                                                                  |   |                    | 30,143,694    |   |             |   | 25,511,360 |   |
| Accumulated      (deficit)                                                                                                                                       |   |                    | (22,541,760   | )      |             |   | (18,744,470 | ) |
| TOTAL      SHAREHOLDERS’ EQUITY                                                                                                                            |   |                    | 8,715,024     |   |             |   | 7,718,316 |   |
| TOTAL      LIABILITIES AND SHAREHOLDERS’ EQUITY                                                                                                            |   | $                       | 9,049,345     |   |             | $      | 8,105,574 |   |

----

|                                                                            |   | Three Months Ended June 30, |       |    | Six Months EndedJune 30, |   |
|---------------------------------------------------------------------------------|--------|-------------------------------------------------|------------|---------|-----------------------------------------|--------|
|                                                                            |   | 2010                                            |       |    | 2009                                    |   |   | 2010 |   |   | 2009 |   |
| Revenue                                                                         |   | $                                               | 8,100      |    |                                    | $      | 71,281 |   |   | $ | 19,250 |   |   | $ | 120,391 |   |
| Cost      of revenue                                                            |   |                                            | 1,269      |    |                                    |   | 58,645 |   |   |   | 3,748 |   |   |   | 80,780 |   |
| Gross      profit                                                               |   |                                            | 6,831      |    |                                    |   | 12,636 |   |   |   | 15,502 |   |   |   | 39,611 |   |
|                                                                            |   |                                            |       |    |                                    |   |   |   |   |   |   |   |   |   |   |   |
| Operating      expenses:                                                        |   |                                            |       |    |                                    |   |   |   |   |   |   |   |   |   |   |   |
| Research      and development                                                   |   |                                            | 463,604    |    |                                    |   | 268,319 |   |   |   | 687,996 |   |   |   | 734,163 |   |
| General      and administrative                                                 |   |                                            | 481,625    |    |                                    |   | 525,537 |   |   |   | 992,913 |   |   |   | 990,312 |   |
| Sales      and marketing                                                        |   |                                            | 111,080    |    |                                    |   | (2,429 | )  |   |   | 203,183 |   |   |   | 184,107 |   |
| Total      operating expenses                                                   |   |                                            | 1,056,309  |    |                                    |   | 791,427 |   |   |   | 1,884,092 |   |   |   | 1,908,582 |   |
| Operating      (loss)                                                           |   |                                            | (1,049,478 | )       |                                    |   | (778,791 | ) |   |   | (1,868,590 | ) |   |   | (1,868,971 | ) |
|                                                                            |   |                                            |       |    |                                    |   |   |   |   |   |   |   |   |   |   |   |
| Other      expense (income), net                                                |   |                                            | 1,106      |    |                                    |   | 3,585 |   |   |   | 2,312 |   |   |   | 748 |   |
| Net      (loss)                                                                 |   |                                            | (1,050,584 | )       |                                    |   | (782,376 | ) |   |   | (1,870,902 | ) |   |   | (1,869,719 | ) |
|                                                                            |   |                                            |       |    |                                    |   |   |   |   |   |   |   |   |   |   |   |
| Deemed      dividend on preferred stock                                         |   |                                            | (1,836,319 | )       |                                    |   | (291,955 | )  |   |   | (1,836,319 | ) |   |   | (291,955 | )  |
|  Accumulated      but unpaid dividend on preferred stock                   |   |                                            | (24,484    | )  |                                    |   | -  |   |   |   | (81,760 | )  |   |   | -  |   |
|      Net      (loss) applicable to common shareholders |   | $                                               | (2,911,387 | )       |                                    |   | (1,074,331 | ) |   | $ | (3,788,981 | ) |   | $ | (2,161,674 | ) |
| Basic      and diluted net (loss) per share                                     |   | $                                               | (0.03      | )       |                                    | $      | (0.02 | ) |   | $ | (0.05 | ) |   | $ | (0.03 | ) |
|      Weighted      average common shares outstanding   |   |                                            | 91,754,282 |    |                                    |   | 69,707,615 |   |   |   | 83,280,115 |   |   |   | 69,616,447 |   |

----

|                                              |   | Preferred Stock |        |    | Common Stock |   |     | AdditionalPaid-In |   |   | Accumulated |   |   | TotalShareholders’ |    |
|---------------------------------------------------|--------|----------------------|-------------|---------|-------------------|--------|----------|-------------------|--------|--------|-------------|--------|--------|--------------------------|---------|
|                                              |   | Shares               |        |    | Amount            |   |     | Shares            |   |   | Amount      |   |   | Capital                  |    |   | Deficit |   |   | Equity |   |
| Balance,      December 31, 2009                   |   |                 | 25,000,000  |    |              | $      | 250,000  |              |   |   | 70,142,615  |   |   | $                        | 701,426 |   |   | $ | 25,511,360 |   |   | $ | (18,744,470 | ) |   | $ | 7,718,316 |   |
|                                              |   |                 |        |    |              |   |     |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock      based compensation – consultants |   |                 |        |    |              |   |     |              |   |   |        |   |   |                     |    |   |   |   | 13,709 |   |   |   |   |   |   |   | 13,709 |   |
| Stock      based compensation – employees   |   |                 |        |    |              |   |     |              |   |   |        |   |   |                     |    |   |   |   | 96,065 |   |   |   |   |   |   |   | 96,065 |   |
| Common      stock issued for services             |   |                 |        |    |              |   |     |              |   |   | 175,000     |   |   |                     | 1,750   |   |   |   | 56,350 |   |   |   |   |   |   |   | 58,100 |   |
| Conversion      of Series B Preferred Stock       |   |                 | (22,115,000 | )  |              |   | (221,150 | )            |   |   | 22,115,000  |   |   |                     | 221,150 |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Sale      of Series C Preferred Stock             |   |                 | 15,766,155  |    |              |   | 157,662  |              |   |   |        |   |   |                     |    |   |   |   | 2,542,074 |   |   |   |   |   |   |   | 2,699,736 |   |
| Deemed      Dividend – Preferred Stock      |   |                 |        |    |              |   |     |              |   |   |        |   |   |                     |    |   |   |   | 1,836,319 |   |   |   | (1,836,319 | ) |   |   |   |   |
| Accrued      Dividend paid in Common Stock        |   |                 |        |    |              |   |     |              |   |   | 225,170     |   |   |                     | 2,252   |   |   |   | 87,818 |   |   |   | 90,069 |   |   |   |   |   |
| Net      loss                                     |   |                 |        |    |              |   |     |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   | (1,870,902 | ) |   |   | (1,870,902 | ) |
| Balance,      June 30, 2010                       |   |                 | 18,651,155  |    |              | $      | 186,512  |              |   |   | 92,657,785  |   |   | $                        | 926,578 |   |   | $ | 30,143,694 |   |   | $ | (22,541,760 | ) |   | $ | 8,715,024 |   |

----

|                                                                                     |   | Six Months EndedJune      30, |       |
|------------------------------------------------------------------------------------------|--------|-----------------------------------------|------------|
|                                                                                     |   | 2010                                    |       |   | 2009 |   |
| OPERATING      ACTIVITIES:                                                               |   |                                    |       |   |   |   |
| Net      loss                                                                            |   | $                                       | (1,870,902 | ) |   | $ | (1,869,719 | ) |
| Adjustments      to reconcile net loss to net cash used in operating      activities:    |   |                                    |       |   |   |   |   |   |
| Depreciation      and amortization                                                       |   |                                    | 163,945    |   |   |   | 187,464 |   |
| Stock-based      compensation employees                                                  |   |                                    | 96,065     |   |   |   | 304,299 |   |
| Stock-based      compensation consultants                                                |   |                                    | 13,709     |   |   |   | 67,848 |   |
|     Amortization      of prepaid financing costs                     |   |                                    | 76,440     |   |   |   | - |   |
|     Impairment      of LUMA equipment                                |   |                                    | 205,406    |   |   |   | - |   |
|     Fair      market value of common stock issued for services       |   |                                    | 58,100     |   |   |   | - |   |
| Changes      in operating assets and liabilities:                                        |   |                                    |       |   |   |   |   |   |
| Accounts      receivable                                                                 |   |                                    | 11,165     |   |   |   | (37,758 | )  |
| Inventory                                                                                |   |                                    | (46,766    | )  |   |   | 146,374 |   |
| Prepaid      expenses and other current assets                                           |   |                                    | 16,430     |   |   |   | 14,829 |   |
| Accounts      payable                                                                    |   |                                    | 11,366     |   |   |   | (119,714 | )  |
| Accrued      liabilities                                                                 |   |                                    | (64,303    | ) |   |   | (20,497 | ) |
| Net      cash used in operating activities                                               |   |                                    | (1,329,345 | ) |   |   | (1,326,874 | ) |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| INVESTING      ACTIVITIES:                                                               |   |                                    |       |   |   |   |   |   |
| Purchases      of fixed assets                                                           |   |                                    | (3,315     | ) |   |   | - |   |
| Net      cash (used in) investing activities                                             |   |                                    | (3,215     | ) |   |   | - |   |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| FINANCING      ACTIVITIES:                                                               |   |                                    |       |   |   |   |   |   |
|        Proceeds      from issuance of Preferred Stock |   |                                    | 2,699,736  |   |   |   | 466,400 |   |
|     Net      cash provided by financing activities                   |   |                                    | 2,699,736  |   |   |   | 466,400 |   |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| Net      (decrease) in cash and cash equivalents                                         |   |                                    | 1,367,076  |   |   |   | (860,474 | ) |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| CASH      AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                    |   |                                    | 3,408,237  |   |   |   | 1,618,181 |   |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| CASH      AND CASH EQUIVALENTS AT END OF PERIOD                                          |   | $                                       | 4,775,313  |   |   | $ | 757,707 |   |
|                                                                                     |   |                                    |       |   |   |   |   |   |
| Supplemental      disclosure of non-cash operating and financing activities:             |   |                                    |       |   |   |   |   |   |
| Stock      issued at fair value for prepaid stock issuance cost                          |   | $                                       | -          |   |   | $ | 273,504 |   |

----

The Company expects to incur significant additional operatinglosses through at least 2010, as it completes clinical trials, beginsoutcome-based clinical studies and increases sales and marketing efforts tocommercialize the WavSTAT and LUMA Systems. If the Company does not receivesufficient funding, the Company may be unable to continue as a going concern.The Company may incur unknown expenses or may not be able to meet its revenueforecast, and one or more of these circumstances would require the Company toseek additional capital. The Company may not be able to obtain equity capital ordebt funding on terms that are acceptable. Even if the Company receivesadditional funding, such proceeds may not be sufficient to allow the Company tosustain operations until it attains profitability and positive cash flows fromoperations.

----

----

|                         |   | 2010         |   |   | 2009         |   |
|------------------------------|--------|--------------|--------|--------|--------------|--------|
| Expected      life           |   | 5      years |   |   | 5 years |   |
| Risk-free      interest rate |   |         | 2.02   | %      |         |   | 2.02 | % |
| Expected      volatility     |   |         | 118    | %      |         |   | 122 | % |
| Expected      dividend yield |   |         | 0      | %      |         |   | 0 | % |

----

|                               |    |                           |    |    | Outstanding Options     |
|------------------------------------|--------------|--------------------------------|--------------|--------------|------------------------------|
|                          |    | OptionsAvailable ForGrant |    |    | Plan OptionsOutstanding |    |    | WeightedAverageExercise PricePer Share |    | Weighted-AverageRemainingContractual Term(years) |   | AggregateIntrinsicValue  |
| December 31, 2009        |         |                           | 3,071,392    |         |                         |   | 7,450,000 |   |   | $ | 0.54 |   | 7.71 |   |  - |
| Options      granted               |         |                           | (800,000     | )            |                         |   | 800,000 |   |   | $ | 0.24 |   |   |   |   |
| Options      exercised             |         |                           | -            |         |                         |   | - |   |   |   | - |   |   |   |   |
| Options      forfeited             |         |                           | 50,000       |         |                         |   | (50,000 | ) |   | $ | 0.80 |   |   |   |   |
| Additional      options authorized |         |                           | 3,377,276    |         |                         |   |     |   |   |   |   |   |   |   |   |
| Outstanding      at June 30, 2010  |         |                           | 5,698,668    |         |                         |   | 8,200,000 |   |   | $ | 0.51 |   | 7.47 |   | - |
| Exercisable      at June 30, 2010  |         |                           |         |         |                         |   | 5,016,667 |   |   | $ | 0.59 |   | 6.46 |   | - |

|                |   | June      30, 2010 |    |   | December 31,2009 |   |
|---------------------|--------|-------------------------|---------|--------|-----------------------|--------|
| Raw      materials  |   | $                       | 230,148 |   |                  | $      | 175,527 |   |
| Finished      goods |   |                    | 222,293 |   |                  |   | 230,148 |   |
| Totals              |   | $                       | 452,441 |   |                  | $      | 405,675 |   |

----

----

|   | · | Continue      selling the WavSTAT System in the U.S. and international markets for the      detection and treatment of pre-cancer and cancer of the    colon. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Complete      WavSTAT System clinical trials related to the diagnosis of esophageal      cancers. |
|--------|--------|---------------------------------------------------------------------------------------------------|

|   | · | Continue      marketing and selling the WavSTAT System in international markets for the      detection of pre-cancer and cancer of the esophagus and in the      U.S. market after FDA approval. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Continue      selling or renting the LUMA System in the U.S. as an adjunct to colposcopy      to specialized OB/GYN clinics, managed care organizations (early detection      and future cost avoidance), teaching hospitals and medical environments      where nurse practitioners and/or medical clinicians can leverage our      technology for effective earlydiagnosis. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Enhance      our San Diego facility and grow our organization to allow for a larger      manufacturing base for both WavSTAT and LUMA Systems and also to continue      the design and planning for the next generation of fluorescence-based      systems. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

Item 3.Quantitative and QualitativeDisclosures About Market Risk

| PART      II | OTHER      INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 1.      | Legal      Proceedings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|         | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 1A.     | Risk      Factors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|         | There      have been no material changes in our risk factors from those disclosed in      Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year      ended December 31, 2009.                                                                                                                                                                                                                                                                                                                                                                                                           |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 2.      | Unregistered      Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|         | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 3.      | Defaults      Upon Senior Securities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|         | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 4.      | (Removed      and Reserved)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 5.      | Other      Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|         | On      April 29, 2010, we designated 25,000,000 of our undesignated shares of      capital stock  as Series C Preferred Stock.  The      Series C Preferred Stock contains the rights and preferences set forth in      the Certificate of Designation of Rights and Preferences of Series C      Preferred Stock, which are generally the same as our Series B Preferred      Stock, but without any cumulative dividend payable.  On April      29, 2010, we also designated an additional 15,000,000 of our undesignated      shares of capital stock as common stock. |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Item 6.      | Exhibits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.1          | Subscription      Agreement for Units Offering (incorporated by reference to exhibit 4.4 to      the Company’s Current Report on Form 8-K (File number 000-13092) as filed      with the SEC on June 24, 2010).                                                                                                                                                                                                                                                                                                                                                                                    |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.2          | Stock      Purchase Warrants for Series C Preferred Stock (incorporated by reference      to exhibit 4.5 to the Company’s Current Report on Form 8-K (File number      000-13092) as filed with the SEC on June 24, 2010).                                                                                                                                                                                                                                                                                                                                                                         |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.3          | Certificate      of Designation for Series C Preferred Stock (incorporated by reference to      exhibit 4.6 to the Company’s Current Report on Form 8-K (File number      000-13092) as filed with the SEC on June 24, 2010).                                                                                                                                                                                                                                                                                                                                                                      |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 4.4          | Certificate      of Designation of Common Stock (incorporated by reference to exhibit 4.7      to the Company’s post-effective amendment No. 1 to registration statement      on Form S-1, as filed with the SEC on May 11, 2010).                                                                                                                                                                                                                                                                                                                                                                 |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 31.1         | Certification      of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 31.2         | Certification      of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 32.1         | Certification      of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 32.2         | Certification      of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley      Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

----

|                      |   | SpectraScience,      Inc.(Registrant)   |   |
|---------------------------|--------|-----------------------------------------|--------|
|                      |   |                                    |   |
| Date      August 16, 2010 |        | /s/      James Hitchin                  |   |
|                      |   | James      Hitchin                      |   |
|                      |   | President,      Chief Executive Officer |   |
|                      |   | (Principal      executive officer)      |   |

|                      |   |                                                                |   |
|---------------------------|--------|---------------------------------------------------------------------|--------|
| Date      August 16, 2010 |        | /s/      James Dorst                                                |   |
|                      |   | James      Dorst                                                    |   |
|                      |   | Chief      Financial Officer                                        |   |
|                      |   | (Principal      financial officer and principal accounting officer) |   |

----